Declaration of Helsinki

Last updated

The Declaration of Helsinki (DoH, Finnish : Helsingin julistus) is a set of ethical principles regarding human experimentation developed originally in 1964 for the medical community by the World Medical Association (WMA). [1] It is widely regarded as the cornerstone document on human research ethics. [1] [2] [3] [4]

Contents

It is not a legally binding instrument under the international law, but instead draws its authority from the degree to which it has been codified in, or influenced, national or regional legislation and regulations. [5] Its role was described by a Brazilian forum in 2000 in these words: "Even though the Declaration of Helsinki is the responsibility of the World Medical Association, the document should be considered the property of all humanity." [5]

Principles

The Declaration is morally binding on physicians, and that obligation overrides any national or local laws or regulations, if the Declaration provides for a higher standard of protection of humans than the latter. Investigators still have to abide by local legislation but will be held to the higher standard.[ citation needed ]

Basic principles

The fundamental principle is respect for the individual (Article 8), his or her right to self-determination and the right to make informed decisions (Articles 20, 21 and 22) regarding participation in research, both initially and during the course of the research. The investigator's duty is solely to the patient (Articles 2, 3 and 10) or volunteer (Articles 16, 18), and while there is always a need for research (Article 6), the participant's welfare must always take precedence over the interests of science and society (Article 5), and ethical considerations must always take precedence over laws and regulations (Article 9).

The recognition of the increased vulnerability of individuals and groups calls for special vigilance (Article 8). It is recognized that when the research participant is incompetent, physically or mentally incapable of giving consent, or is a minor (Articles 23, 24), then allowance should be considered for surrogate consent by an individual acting in the participant's best interest, although his or her consent should still be obtained if at all possible (Article 25).

Operational principles

Research should be based on a thorough knowledge of the scientific background (Article 11), a careful assessment of risks and benefits (Articles 16, 17), have a reasonable likelihood of benefit to the population studied (Article 19) and be conducted by suitably trained investigators (Article 15) using approved protocols, subject to independent ethical review and oversight by a properly convened committee (Article 13). The protocol should address the ethical issues and indicate that it is in compliance with the Declaration (Article 14). Studies should be discontinued if the available information indicates that the original considerations are no longer satisfied (Article 17). Information regarding the study should be publicly available (Article 16). Ethical principles extend to publication of the results and consideration of any potential conflict of interest (Article 27). Experimental investigations should always be compared against the best methods, but under certain circumstances a placebo or no treatment group may be utilized (Article 29). The interests of the participant after the study is completed should be part of the overall ethical assessment, including assuring their access to the best proven care (Article 30). Wherever possible unproven methods should be tested in the context of research where there is reasonable belief of possible benefit (Article 32).

Additional guidelines or regulations

Investigators often find themselves in the position of having to follow several different codes or guidelines, and are therefore required to understand the differences between them. One of these is Good Clinical Practice (GCP), an international guide, while each country may also have local regulations such as the Common Rule in the US, in addition to the requirements of the FDA and Office for Human Research Protections (OHRP) in that country. There are a number of available tools which compare these. [6] Other countries have guides with similar roles, such as the Tri-Council Policy Statement in Canada. Additional international guidelines include those of the CIOMS, Nuffield Council and UNESCO.

History

The Declaration was originally adopted in June 1964 in Helsinki, Finland, and has since undergone eight revisions (the most recent at the General Assembly in October 2024) and two clarifications, growing considerably in length from 11 paragraphs in 1964 to 37 in the 2024 version. [7] The Declaration is an important document in the history of research ethics as it is the first significant effort of the medical community to regulate research itself, and forms the basis of most subsequent documents.

Prior to the 1947 Nuremberg Code there was no generally accepted code of conduct governing the ethical aspects of human research, although some countries, notably Germany and Russia, had national policies [3a]. The Declaration developed the ten principles first stated in the Nuremberg Code, and tied them to the Declaration of Geneva (1948), a statement of physicians' ethical duties. The Declaration more specifically addressed clinical research, reflecting changes in medical practice from the term 'Human Experimentation' used in the Nuremberg Code. A notable change from the Nuremberg Code was a relaxation of the conditions of consent, which was 'absolutely essential' under Nuremberg. Now doctors were asked to obtain consent 'if at all possible' and research was allowed without consent where a proxy consent, such as a legal guardian, was available (Article II.1).

First revision (1975)

The 1975 revision was almost twice the length of the original. It clearly stated that "concern for the interests of the subject must always prevail over the interests of science and society." [8] It also introduced the concept of oversight by an 'independent committee' (Article I.2) which became a system of Institutional Review Boards (IRB) in the US, and research ethics committees or ethical review boards in other countries. [9] In the United States regulations governing IRBs came into effect in 1981 and are now encapsulated in the Common Rule. Informed consent was developed further, made more prescriptive and partly moved from 'Medical Research Combined with Professional Care' into the first section (Basic Principles), with the burden of proof for not requiring consent being placed on the investigator to justify to the committee. 'Legal guardian' was replaced with 'responsible relative'. The duty to the individual was given primacy over that to society (Article I.5), and concepts of publication ethics were introduced (Article I.8). Any experimental manoeuvre was to be compared to the best available care as a comparator (Article II.2), and access to such care was assured (Article I.3). The document was also made gender neutral.

Second to fourth revisions (1975–2000)

Subsequent revisions between 1975 and 2000 were relatively minor, so the 1975 version was effectively that which governed research over a quarter of a century of relative stability.

Second and third revisions (1983, 1989)

The second revision (1983) included seeking the consent of minors where possible. The third revision (1989) dealt further with the function and structure of the independent committee. However, from 1993 onwards, the Declaration was not alone as a universal guide since CIOMS and the World Health Organization (WHO) had also developed their International Ethical Guidelines for Biomedical Research Involving Human Subjects.

Fourth revision (1996)

Background

The AIDS Clinical Trials Group (ACTG) Study 076 of 100 Zidovudine in maternal-infant transmission of HIV had been published in 1994. [10] This was a placebo controlled trial which showed a reduction of nearly 70% in the risk of transmission, and Zidovudine became a de facto standard of care. The subsequent initiation of further placebo controlled trials carried out in developing countries and funded by the United States Centers for Disease Control or National Institutes of Health raised considerable concern when it was learned that patients in trials in the US had essentially unrestricted access to the drug, while those in developing countries did not. Justification was provided by a 1994 WHO group in Geneva which concluded "Placebo-controlled trials offer the best option for a rapid and scientifically valid assessment of alternative antiretroviral drug regimens to prevent transmission of HIV". [11] These trials appeared to be in direct conflict with recently published guidelines [12] for international research by CIOMS, which stated "The ethical standards applied should be no less exacting than they would be in the case of research carried out in country", referring to the sponsoring or initiating country. [13] In fact a schism between ethical universalism [14] and ethical pluralism [15] was already apparent before the 1993 revision of the CIOMS guidelines. [12]

Fourth revision

In retrospect, this was one of the most significant revisions because it added the phrase "This does not exclude the use of inert placebo in studies where no proven diagnostic or therapeutic method exists" to Article II.3 ("In any medical study, every patient--including those of a control group, if any—should be assured of the best proven diagnostic and therapeutic method."). Critics claimed that the Zidovudine trials in developing countries were in breach of this because Zidovudine was now the best proven treatment and the placebo group should have been given it. [16] This led to the US Food and Drug Administration (FDA) ignoring this and all subsequent revisions. [17] [18]

Fifth revision (2000)

Background

Following the fourth revision in 1996 pressure began to build almost immediately for a more fundamental approach to revising the declaration. [19] The later revision in 2000 would go on to require monitoring of scientific research on human subjects to assure ethical standards were being met. [20] In 1997 Lurie and Wolfe published their seminal paper on HIV trials, [21] raising awareness of a number of central issues. These included the claims that the continuing trials in developing countries were unethical, and pointing out a fundamental discrepancy in decisions to change the study design in Thailand but not Africa. The issue of the use of placebo in turn raised questions about the standard of care in developing counties and whether, as Marcia Angell wrote "Human subjects in any part of the world should be protected by an irreducible set of ethical standards" (1988). The American Medical Association put forward a proposed revision in November that year, [22] [23] and a proposed revision (17.C/Rev1/99) was circulated the following year, [24] [25] causing considerable debate and resulting in a number of symposia and conferences. [26] Recommendations included limiting the document to basic guiding principles. [27] [28] Many editorials and commentaries were published reflecting a variety of views including concerns that the Declaration was being weakened by a shift towards efficiency-based and utilitarian standards (Rothman, Michaels and Baum 2000), [29] [30] [31] [32] and an entire issue of the Bulletin of Medical Ethics was devoted to the debate. Others saw it as an example of Angell's 'Ethical Imperialism', an imposition of US needs on the developing world, [33] and resisted any but the most minor changes, or even a partitioned document with firm principles and commentaries, as used by CIOMS. The idea of ethical imperialism was brought into high attention with HIV testing, as it was strongly debated from 1996 to 2000 because of its centrality to the issue of regimens to prevent its vertical transmission. [20] Brennan summarises this by stating "The principles exemplified by the current Declaration of Helsinki represent a delicate compromise that we should modify only after careful deliberation". Nevertheless, what had started as a controversy over a specific series of trials and their designs in Sub-Saharan Africa, now had potential implications for all research. These implications further came into public view since the Helsinki declaration had stated, "In the treatment of the sick person, the physician must be free to use a new diagnostic and therapeutic measure, if in his or her judgement, it offers hope of saving life, reestablishing health or alleviating suffering." [34]

Fifth revision

Even though most meetings about the proposed revisions failed to achieve consensus, and many argued that the declaration should remain unchanged or only minimally altered, after extensive consultation the Workgroup [35] eventually came up with a text what that was endorsed by WMA's Council and passed by the General Assembly on October 7, 2000, [36] and which proved to be the most far reaching and contentious revision to date. The justification for this was partly to take account of expanded scope of biomedical research since 1975. [37] This involved a restructuring of the document, including renumbering and re-ordering of all the articles, the changes in which are outlined in this Table Archived 2010-06-05 at the Wayback Machine . The Introduction establishes the rights of subjects and describes the inherent tension between the need for research to improve the common good, and the rights of the individual. The Basic Principles establish a guide for judging to what extent proposed research meets the expected ethical standards. The distinction between therapeutic and non-therapeutic research introduced in the original document, criticised by Levine [19] [38] was removed to emphasize the more general application of ethical principles, but the application of the principles to healthy volunteers is spelt out in Articles 18–9, and they are referred to in Article 8 ('those who will not benefit personally from the research') as being especially vulnerable. The scope of ethical review was increased to include human tissue and data (Article 1), the necessity to challenge accepted care was added (Article 6), as well as establishing the primacy of the ethical requirements over laws and regulations (Article 9).

Amongst the many changes was an increased emphasis on the need to benefit the communities in which research is undertaken, and to draw attention to the ethical problems of experimenting on those who would not benefit from the research, such as developing countries in which innovative medications would not be available. Article 19 first introduces the concept of social justice, and extends the scope from individuals to the community as a whole by stating that 'research is only justified if there is a reasonable likelihood that the populations in which the research is carried out stand to benefit from the results of the research'. This new role for the Declaration has been both denounced [18] and praised, [39] Macklin R. Future challenges for the Declaration of Helsinki: Maintaining credibility in the face of ethical controversies. Address to Scientific Session, World Medical Association General Assembly, September 2003, Helsinki and even considered for a clarification footnote. [40] Article 27 expanded the concept of publication ethics, adding the necessity to disclose conflict of interest (echoed in Articles 13 and 22), and to include publication bias amongst ethically problematic behavior.

Additional principles

The most controversial revisions [39] (Articles 29, 30) were placed in this new category. These predictably were those that like the fourth revision were related to the ongoing debate in international health research. The discussions [36] indicate that there was felt a need to send a strong signal that exploitation of poor populations as a means to an end, by research from which they would not benefit, was unacceptable. In this sense the Declaration endorsed ethical universalism.

Article 29 restates the use of placebo where 'no proven' intervention exists. Surprisingly, although the wording was virtually unchanged, this created far more protest in this revision. The implication being that placebos are not permitted where proven interventions are available. The placebo question was already an active debate prior to the fourth revision but had intensified, while at the same time the placebo question was still causing controversy in the international setting. This revision implies that in choosing a study design, developed-world standards of care should apply to any research conducted on human subjects, including those in developing countries. The wording of the fourth and fifth revisions reflect the position taken by Rothman and Michel [41] and Freedman et al., [42] known as 'active-control orthodoxy'. The opposing view, as expressed by Levine [19] and by Temple and Ellenberg [43] is referred to as 'placebo orthodoxy', insisting that placebo controls are more scientifically efficient and are justifiable where the risk of harm is low. This viewpoint argues that where no standards of care exist, as for instance in developing countries, then placebo-controlled trials are appropriate. The utilitarian argument [44] held that the disadvantage to a few (such as denial of potentially beneficial interventions) was justifiable for the advantage of many future patients. These arguments are intimately tied to the concept of distributive justice, the equitable distribution of the burdens of research. [32] [45] As with much of the Declaration, there is room for interpretation of words. 'Best current' has been variously held to refer to either global or local contexts. [46]

Article 30 introduced another new concept, that after the conclusion of the study patients 'should be assured of access to the best proven' intervention arising from the study, a justice issue. Arguments over this have dealt with whether subjects derive benefit from the trial and are no worse off at the end than the status quo prior to the trial, or of not participating, versus the harm of being denied access to that which they have contributed to. There are also operational issues that are unclear.

Aftermath

Given the lack of consensus on many issues prior to the fifth revision it is no surprise that the debates continued unabated. [39] [47] The debate over these and related issues also revealed differences in perspectives between developed and developing countries. [48] [49] [50] Zion and colleagues (Zion 2000) [30] [48] have attempted to frame the debate more carefully, exploring the broader social and ethical issues and the lived realities of potential subjects' lives as well as acknowledging the limitations of absolute universality in a diverse world, particularly those framed in a context that might be considered elitist and structured by gender and geographic identity. As Macklin [39] points out, both sides may be right, since justice "is not an unambiguous concept".

Clarifications of Articles 29, 30 (2002–2004)

Eventually Notes of Clarification (footnotes) to articles 29 and 30 were added in 2002 and 2004 respectively, predominantly under pressure from the US (CMAJ 2003, Blackmer 2005). The 2002 clarification to Article 29 was in response to many concerns about WMA's apparent position on placebos. As WMA states in the note, there appeared to be 'diverse interpretations and possibly confusion'. It then outlined circumstances in which a placebo might be 'ethically acceptable', namely 'compelling... methodological reasons', or 'minor conditions' where the 'risk of serious or irreversible harm' was considered low. Effectively this shifted the WMA position to what has been considered a 'middle ground'. [51] [52] Given the previous lack of consensus, this merely shifted the ground of debate, [39] which now extended to the use of the 'or' connector. For this reason the footnote indicates that the wording must be interpreted in the light of all the other principles of the Declaration.

Article 30 was debated further at the 2003 meeting, with another proposed clarification [50] but did not result in any convergence of thought, and so decisions were postponed for another year, [53] [54] but again a commitment was made to protecting the vulnerable. A new working group examined article 30, and recommended not amending it in January 2004. [55] Later that year the American Medical Association proposed a further note of clarification that was incorporated. [56] In this clarification the issue of post trial care now became something to consider, not an absolute assurance.

Despite these changes, as Macklin predicted, consensus was no closer and the Declaration was considered by some to be out of touch with contemporary thinking, [57] and even the question of the future of the Declaration became a matter for conjecture. [58]

Considerable deliberation has taken place regarding the most effective approach to address the concerns related to paragraph 30. Two distinct working groups have explored this matter and put forth various suggestions, which encompass potential revisions to the paragraph, the inclusion of a preamble, and the introduction of a clarifying note (similar to what was incorporated into paragraph 29). At a gathering of the WMA Council in France in May 2004, the American Medical Association presented the subsequent clarifying statement:

The WMA reaffirms its stance that it is imperative, within the study planning phase, to identify provisions for post-trial access by research participants to prophylactic, diagnostic, and therapeutic procedures deemed beneficial in the study or to access to other appropriate healthcare. The specifics of post-trial access arrangements or alternative care should be outlined in the study protocol, enabling the ethical review committee to evaluate these provisions during its assessment. [56]

Sixth revision (2008)

The sixth revision cycle commenced in May 2007. This consisted of a call for submissions, completed in August 2007. The terms of reference included only a limited revision compared to 2000. [59] In November 2007 a draft revision was issued for consultation until February 2008, [60] and led to a workshop in Helsinki in March. [61] Those comments were then incorporated into a second draft in May. [62] [63] Further workshops were held in Cairo and São Paulo and the comments collated in August 2008. A final text was then developed by the Working Group for consideration by the Ethics Committee and finally the General Assembly, which approved it on October 18. Public debate was relatively slight compared to previous cycles, and in general supportive. [64] Input was received from a wide number of sources, some of which have been published, such as Feminist Approaches to Bioethics. [65] Others include CIOMS and the US Government. [66]

Seventh revision (2013)

The seventh revision of Helsinki (2013) was reflective of the controversy regarding the standard of care that arose from the vertical transmission trials. The revised declaration of 2013 also highlights the need to disseminate research results, including negative and inconclusive studies and also includes a requirement for treatment and compensation for injuries related to research. [67] In addition, the updated version is felt to be more relevant to limited resource settings—specifically addressing the need to ensure access to an intervention if it is proven effective.

Eighth revision (2024)

The eighth revision of Helsinki (2024) newly highlights the roles of global inequities in medical research and includes a new statement that scientific integrity "is essential in the conduct of medical research involving human participants. Involved individuals, teams, and organizations must never engage in research misconduct". [7]

Future

The controversies and national divisions over the text have continued. The US FDA rejected the 2000 and subsequent revisions, only recognizing the third (1989) revision, [58] and in 2006 announced it would eliminate all reference to the Declaration. After consultation, which included expressions of concern, [68] a final rule was issued on April 28, 2008, replacing the Declaration of Helsinki with Good Clinical Practice effective October 2008. [69] This has raised a number of concerns regarding the apparent weakening of protections for research subjects outside the United States. [70] [71] [72] [73] [74] [75] [76] [77] [78] The NIH training in human subject research participant protection no longer refers to the Declaration of Helsinki. The European Union similarly only cites the 1996 version in the EU Clinical Trials Directive published in 2001. [79] The European Commission, however, does refer to the 2000 revision. [80]

While the Declaration has been a central document guiding research practice, its future has been called into question. Challenges include the apparent conflict between guides, such as the CIOMS and Nuffield Council documents. Another is whether it should concentrate on basic principles as opposed to being more prescriptive, and hence controversial. It has continually grown and faced more frequent revisions. [40] The recent controversies undermine the authority of the document, as does the apparent desertion by major bodies, and any rewording must embrace deeply and widely held values, since continual shifts in the text do not imply authority. The actual claim to authority, particularly on a global level, by the insertion of the word "international" in article 10 has been challenged. [81]

Carlson raises the question as to whether the document's utility should be more formally evaluated, rather than just relying on tradition.

The Declaration's long-standing pre-eminence

There appears to be a noticeable trend toward more frequent changes in the Declaration of Helsinki (DoH). However, it's important to note that only two of the revisions, in 1975 and 2000, introduced significant alterations. [40] This means that there was an 11-year gap between comprehensive revisions (from 1964 to 1975) and a 25-year gap (from 1975 to 2000), respectively. Consequently, the DoH, essentially in its 1975 version, had a quarter-century to establish itself within the medical research community, and this has significantly contributed to its current status.

The World Medical Association (WMA)

One potential explanation is that it derives its legitimacy from being an official declaration of the World Medical Association (WMA). This organization represents the largest global assembly of physicians, and consequently, it could be argued that the WMA is a credible and authoritative entity for issuing statements on behalf of the medical profession as a whole. [40]

However, a historical observation appears to challenge the notion that this explains the Declaration of Helsinki's authority. It can be argued that the Declaration was most widely accepted as an authoritative document during the period from the late 1970s (after the 1975 amendment had been widely promulgated) to the mid-to-late 1990s when increasing demands for changes to the Declaration began to emerge. Notably, this period was marked by significant internal unrest within the WMA. In the 1980s, a group of countries, known as the 'Toronto Group,' which included the UK, withdrew from the WMA due to persistent objections related to the South African Medical Association's failure to denounce apartheid. Historical events eventually led to the reconciliation of this division, and all the countries that had previously withdrawn had rejoined the WMA by 1995. [82]

Timeline (WMA meetings)

Other notable developments

See also

Related Research Articles

The Nuremberg Code is a set of ethical research principles for human experimentation created by the court in U.S. v Brandt, one of the Subsequent Nuremberg trials that were held after the Second World War.

<span class="mw-page-title-main">Hippocratic Oath</span> Oath of ethics taken by physicians

The Hippocratic Oath is an oath of ethics historically taken by physicians. It is one of the most widely known of Greek medical texts. In its original form, it requires a new physician to swear, by a number of healing gods, to uphold specific ethical standards. The oath is the earliest expression of medical ethics in the Western world, establishing several principles of medical ethics which remain of paramount significance today. These include the principles of medical confidentiality and non-maleficence. As the foundational articulation of certain principles that continue to guide and inform medical practice, the ancient text is of more than historic and symbolic value. It is enshrined in the legal statutes of various jurisdictions, such that violations of the oath may carry criminal or other liability beyond the oath's symbolic nature.

<span class="mw-page-title-main">Placebo</span> Substance or treatment of no therapeutic value

A placebo is a substance or treatment which is designed to have no therapeutic value. Common placebos include inert tablets, inert injections, sham surgery, and other procedures.

Bioethics is both a field of study and professional practice, interested in ethical issues related to health, including those emerging from advances in biology, medicine, and technologies. It proposes the discussion about moral discernment in society and it is often related to medical policy and practice, but also to broader questions as environment, well-being and public health. Bioethics is concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, theology and philosophy. It includes the study of values relating to primary care, other branches of medicine, ethical education in science, animal, and environmental ethics, and public health.

Medical ethics is an applied branch of ethics which analyzes the practice of clinical medicine and related scientific research. Medical ethics is based on a set of values that professionals can refer to in the case of any confusion or conflict. These values include the respect for autonomy, non-maleficence, beneficence, and justice. Such tenets may allow doctors, care providers, and families to create a treatment plan and work towards the same common goal. These four values are not ranked in order of importance or relevance and they all encompass values pertaining to medical ethics. However, a conflict may arise leading to the need for hierarchy in an ethical system, such that some moral elements overrule others with the purpose of applying the best moral judgement to a difficult medical situation. Medical ethics is particularly relevant in decisions regarding involuntary treatment and involuntary commitment.

<span class="mw-page-title-main">Clinical trial</span> Phase of clinical research in medicine

Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments and known interventions that warrant further study and comparison. Clinical trials generate data on dosage, safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial—their approval does not mean the therapy is 'safe' or effective, only that the trial may be conducted.

<span class="mw-page-title-main">Human subject research</span> Systematic, scientific investigation that involves human beings as research subjects

Human subject research is systematic, scientific investigation that can be either interventional or observational and involves human beings as research subjects, commonly known as test subjects. Human subject research can be either medical (clinical) research or non-medical research. Systematic investigation incorporates both the collection and analysis of data in order to answer a specific question. Medical human subject research often involves analysis of biological specimens, epidemiological and behavioral studies and medical chart review studies. On the other hand, human subject research in the social sciences often involves surveys which consist of questions to a particular group of people. Survey methodology includes questionnaires, interviews, and focus groups.

The regulation of science refers to use of law, or other ruling, by academic or governmental bodies to allow or restrict science from performing certain practices, or researching certain scientific areas.

An institutional review board (IRB), also known as an independent ethics committee (IEC), ethical review board (ERB), or research ethics board (REB), is a committee at an institution that applies research ethics by reviewing the methods proposed for research involving human subjects, to ensure that the projects are ethical. The main goal of IRB reviews is to ensure that study participants are not harmed. Such boards are formally designated to approve, monitor, and review biomedical and behavioral research involving humans, and they are legally required in some countries under certain specified circumstances. Most countries use some form of IRB to safeguard ethical conduct of research so that it complies with national and international norms, regulations or codes.

In drug development and production, good clinical practice (GCP) is an international quality standard, which governments can then transpose into regulations for clinical trials involving human subjects. GCP follows the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), and enforces tight guidelines on ethical aspects of clinical research.

<span class="mw-page-title-main">Council for International Organizations of Medical Sciences</span> International non-governmental medical science organization

The Council for International Organizations of Medical Sciences (CIOMS) is an international non-governmental organization of 40 international, national, and associate member groups representing the biomedical science community. It was jointly established by the World Health Organization (WHO) and United Nations Educational, Scientific and Cultural Organization (UNESCO) in 1949 as a successor to the International Medical Congress that organized 17 conferences from 1867 until the 1913 outbreak of World War I.

<span class="mw-page-title-main">Research ethics</span> Ethical practice in scientific research

Research ethics is a discipline within the study of applied ethics. Its scope ranges from general scientific integrity and misconduct to the treatment of human and animal subjects. The social responsibilities of scientists and researchers are not traditionally included and are less well defined.

<span class="mw-page-title-main">Henry K. Beecher</span> American medical academic

Henry Knowles Beecher was a pioneering American anesthesiologist, medical ethicist, and investigator of the placebo effect at Harvard Medical School.

An ethics committee is a body responsible for ensuring that medical experimentation and human subject research are carried out in an ethical manner in accordance with national and international law.

<span class="mw-page-title-main">Children in clinical research</span>

In health care, a clinical trial is a comparison test of a medication or other medical treatment, versus a placebo, other medications or devices, or the standard medical treatment for a patient's condition.

<span class="mw-page-title-main">Placebo-controlled study</span>

Placebo-controlled studies are a way of testing a medical therapy in which, in addition to a group of subjects that receives the treatment to be evaluated, a separate control group receives a sham "placebo" treatment which is specifically designed to have no real effect. Placebos are most commonly used in blinded trials, where subjects do not know whether they are receiving real or placebo treatment. Often, there is also a further "natural history" group that does not receive any treatment at all.

Ruth Macklin is an American philosopher and retired professor of bioethics.

The term informed assent describes the process whereby minors may agree to participate in clinical trials. It is similar to the process of informed consent in adults, however there remains some overlap between the terms.

The philosophy of medicine is a branch of philosophy that explores issues in theory, research, and practice within the field of health sciences, more specifically in topics of epistemology, metaphysics, and medical ethics, which overlaps with bioethics. Philosophy and medicine, have had a long history of overlapping ideas. It was not until the nineteenth century that the professionalization of the philosophy of medicine came to be. In the late twentieth century, debates among philosophers and physicians ensued of whether the philosophy of medicine should be considered a field of its own from either philosophy or medicine. A consensus has since been reached that it is in fact a distinct discipline with its set of separate problems and questions. In recent years there have been a variety of university courses, journals, books, textbooks and conferences dedicated to the philosophy of medicine.

Vasantha Muthuswamy was an Indian physician and bioethicist, head of the Indian Council of Medical Research's Division of Basic Medical Sciences, Traditional Medicine, and Bioethics, and the Division of Reproductive Health and Nutrition, from 1990 to 2008. She was a leader in establishing, revising, and promoting ethical guidelines for medical research in India. She participated in international organizations and projects focused on bioethics, and was a noted critic of ethics dumping.

References

  1. 1 2 World Medical Association (2013). "Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects". JAMA. 310 (20): 2191–2194. doi: 10.1001/jama.2013.281053 . hdl: 10818/33790 . PMID   24141714.
  2. ↑ "WMA Press Release: WMA revises the Declaration of Helsinki. 9 October 2000". Archived from the original on September 27, 2006.
  3. ↑ Snežana, Bošnjak (2001). "The declaration of Helsinki: The cornerstone of research ethics". Archive of Oncology. 9 (3): 179–84.
  4. ↑ Tyebkhan, G (2003). "Declaration of Helsinki: the ethical cornerstone of human clinical research". Indian Journal of Dermatology, Venereology and Leprology. 69 (3): 245–7. PMID   17642902.
  5. 1 2 Human, Delon; Fluss, Sev S. (July 24, 2001). "The World Medical Association's Declaration of Helsinki: Historical and contemporary perspectives. 5th draft" (PDF). World Medical Association. Archived from the original (PDF) on October 6, 2016. Retrieved July 18, 2016.
  6. ↑ Toxicology Excellence for Risk Assessment (August 2002). "Comparison of Common Rule with the Declaration of Helsinki and Good Clinical Practice" (PDF). Retrieved 26 August 2012.
  7. 1 2 "Declaration of Helsinki History Website". Ethical Principles For Medical Research. The JAMA Network. Retrieved 22 October 2024.
  8. ↑ Vanderpool, Harold Y. (1996). The Ethics of Research Involving Human Subjects: Facing the 21st Century. Frederick, Maryland: University Publishing Group, Inc. p. 85. ISBN   1-55572-036-6
  9. ↑ Riis P (July 1977). "Letter from...Denmark. Planning of scientific-ethical committees". British Medical Journal. 2 (6080): 173–4. doi:10.1136/bmj.2.6080.173. PMC   1631019 . PMID   871832.
  10. ↑ Connor, Edward M.; Sperling, Rhoda S.; Gelber, Richard; Kiselev, Pavel; Scott, Gwendolyn; O'Sullivan, Mary Jo; VanDyke, Russell; Bey, Mohammed; Shearer, William (1994-11-03). "Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment". New England Journal of Medicine. 331 (18): 1173–1180. doi: 10.1056/NEJM199411033311801 . ISSN   0028-4793. PMID   7935654.
  11. ↑ Recommendations from the Meeting on Prevention of Mother-to-Infant Transmission of HIV by Use of Antiretrovirals. World Health Organization. June 23, 1994.
  12. 1 2 Levine RJ (August 1993). "New international ethical guidelines for research involving human subjects". Annals of Internal Medicine. 119 (4): 339–41. doi:10.7326/0003-4819-119-4-199308150-00016. PMID   8328746. S2CID   45747064.
  13. ↑ Council for International Organizations of Medical Sciences (1993). "Guideline 11: Selection of pregnant or nursing (breastfeeding) women as research subjects". International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva: World Health Organization. ISBN   978-92-9036-056-8. Archived from the original on 2010-03-05. Retrieved 2010-09-02.
  14. ↑ Angell M (October 1988). "Ethical imperialism? Ethics in international collaborative clinical research". The New England Journal of Medicine. 319 (16): 1081–3. doi:10.1056/NEJM198810203191608. PMID   3173435.
  15. ↑ Barry M (October 1988). "Ethical considerations of human investigation in developing countries: the AIDS dilemma". The New England Journal of Medicine. 319 (16): 1083–6. doi:10.1056/NEJM198810203191609. PMID   3173436.
  16. ↑ Levine, Robert J. (2006). "Some Recent Developments in the International Guidelines on the Ethics of Research Involving Human Subjectsa". Annals of the New York Academy of Sciences. 918 (1): 170–8. Bibcode:2000NYASA.918..170L. doi:10.1111/j.1749-6632.2000.tb05486.x. PMID   11131702. S2CID   32192360.
  17. ↑ Health, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological (2019-04-20). "Search for FDA Guidance Documents - Acceptance of Foreign Clinical Studies". www.fda.gov.{{cite web}}: CS1 maint: multiple names: authors list (link)
  18. 1 2 Temple R. Impact of the Declaration of Helsinki on medical research from a regulatory perspective. Address to the Scientific Session, World Medical Association General Assembly, September 2003.
  19. 1 2 3 Levine RJ (August 1999). "The need to revise the Declaration of Helsinki". The New England Journal of Medicine. 341 (7): 531–4. doi:10.1056/NEJM199908123410713. PMID   10441613.
  20. 1 2 Grady, Christine; Forster, Heidi P.; Emanuel, Ezekiel (October 2001). "The 2000 Revision of the Declaration of Helsinki: A Step Forward or More Confusion?". The Lancet (Submitted manuscript). 358 (9291): 1449–1453. doi:10.1016/S0140-6736(01)06534-5. PMID   11705513. S2CID   32531949.
  21. ↑ Lurie P, Wolfe SM (September 1997). "Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries". The New England Journal of Medicine. 337 (12): 853–6. doi:10.1056/NEJM199709183371212. PMID   9295246.
  22. ↑ General Assembly WMA Hamburg, Germany 1997
  23. ↑ "Americans want to water down Helsinki Declaration". Bulletin of Medical Ethics. 136: 3–4. 1998. PMID   11657531.
  24. ↑ "Harvard Kennedy School Case Program". www.ksg.harvard.edu. 14 March 2024.
  25. ↑ World Medical, Association (1999). "Proposed revision of the Declaration of Helsinki". Bulletin of Medical Ethics. 147: 18–22. PMID   11657218.
  26. ↑ Nicholson, RH; Crawley, FP (1999). "Revising the Declaration of Helsinki: a fresh start". Bulletin of Medical Ethics. 151: 13–7. PMID   11657985.
  27. ↑ WMA Medical Ethics Committee (1999). "Updating the WMA Declaration of Helsinki". WLD Med J. 45: 11–13.
  28. ↑ Deutsch E, Taupitz J (1999). "Göttingen Report. Freedom and control of biomedical research- the planned revision of the Declaration of Helsinki". WLD Med J. 45: 40–41.
  29. ↑ Stockhausen, K (2000). "The Declaration of Helsinki: revising ethical research guidelines for the 21st century". The Medical Journal of Australia. 172 (6): 252–3. doi:10.5694/j.1326-5377.2000.tb123936.x. PMID   10860086. S2CID   6224890.
  30. 1 2 Loff, B; Black, J (2000). "The Declaration of Helsinki and research in vulnerable populations". The Medical Journal of Australia. 172 (6): 292–5. doi:10.5694/j.1326-5377.2000.tb123950.x. PMID   10860097. S2CID   22564170.
  31. ↑ Loff, Bebe; Gillam, Deborah; Loff, Lynn (2000). "The Declaration of Helsinki, CIOMS and the ethics of research on vulnerable populations". Nature Medicine. 6 (6): 615–7. doi:10.1038/76174. PMID   10835665. S2CID   35158750.
  32. 1 2 Brennan TA (August 1999). "Proposed revisions to the Declaration of Helsinki--will they weaken the ethical principles underlying human research?". The New England Journal of Medicine. 341 (7): 527–31. doi:10.1056/NEJM199908123410712. PMID   10441612.
  33. ↑ Nicholson, RH (2000). "If it ain't broke, don't fix it". Hastings Center Report . 30 (1): 6. doi:10.2307/3527987. JSTOR   3527987. PMID   11645209.
  34. ↑ Vanderpool, Harold Y. (1996). The Ethics of Research Involving Human Subjects: Facing the 21st Century. Frederick, Maryland: University Publishing Group, Inc. pp.  433–436. ISBN   978-1-55572-036-0.
  35. ↑ Nancy Dickey, Kati Myllymäki, Judith Kazimirsky
  36. 1 2 Christie B (October 2000). "Doctors revise Declaration of Helsinki". BMJ. 321 (7266): 913. doi:10.1136/bmj.321.7266.913. PMC   1118720 . PMID   11030663.
  37. ↑ Riis, Povl (December 20, 2000). "Perspectives on the Fifth Revision of the Declaration of Helsinki". JAMA. 284 (23): 3045–3046. doi:10.1001/jama.284.23.3045. PMID   11122594 – via Silverchair.
  38. ↑ Levine, RJ (2000). "Some recent developments in the international guidelines on the ethics of research involving human subjects". Annals of the New York Academy of Sciences. 918 (1): 170–8. Bibcode:2000NYASA.918..170L. doi:10.1111/j.1749-6632.2000.tb05486.x. PMID   11131702. S2CID   32192360.
  39. 1 2 3 4 5 "Macklin R. After Helsinki: Unresolved issues in international research. Kennedy Inst Ethics J 2001 11(1): 17-36 (password required)".
  40. 1 2 3 4 Carlson, Robert V.; Boyd, Kenneth M.; Webb, David J. (2004). "The revision of the Declaration of Helsinki: past, present and future". British Journal of Clinical Pharmacology. 57 (6): 695–713. doi:10.1111/j.1365-2125.2004.02103.x. PMC   1884510 . PMID   15151515.
  41. ↑ Rothman KJ, Michels KB (August 1994). "The continuing unethical use of placebo controls". The New England Journal of Medicine. 331 (6): 394–8. doi:10.1056/NEJM199408113310611. PMID   8028622.
  42. ↑ Freedman B, Weijer C, Glass KC (1996). "Placebo orthodoxy in clinical research. I: Empirical and methodological myths". The Journal of Law, Medicine & Ethics. 24 (3): 243–51. doi:10.1111/j.1748-720X.1996.tb01859.x. PMID   9069851. S2CID   19346751.
  43. ↑ Temple, R; Ellenberg, SS (2000). "Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues". Annals of Internal Medicine. 133 (6): 455–63. doi:10.7326/0003-4819-133-6-200009190-00014. PMID   10975964. S2CID   10749308.
  44. ↑ Elander G, Hermerén G (June 1995). "Placebo effect and randomized clinical trials". Theoretical Medicine. 16 (2): 171–82. doi:10.1007/BF00998543. PMID   7570396. S2CID   30039309.
  45. ↑ Benatar, S. R. (2001). "Distributive justice and clinical trials in the Third World". Theoretical Medicine and Bioethics. 22 (3): 169–176. doi:10.1023/A:1011419820440. PMID   11499493. S2CID   33645553.
  46. ↑ "Nuffield Council on Bioethics: The ethics of research related to healthcare in developing countries. 2005" (PDF). Archived from the original (PDF) on 2007-09-28. Retrieved 2007-08-21.
  47. ↑ Williams JR. The promise and limits of international bioethics: Lessons from the recent revision of the Declaration of Helsinki. Int J Bioethics 2004 15(1): 31-42
  48. 1 2 Loff, B (2000). "Violence in research". The Lancet. 355 (9217): 1806. doi:10.1016/S0140-6736(00)02310-2. PMID   10832846. S2CID   20338322.
  49. ↑ "Schuklenk U. Helsinki Declaration revisions. Indian Journal of Medical Ethics. Jan-Mar 2001 9(1)".
  50. 1 2 <Please add first missing authors to populate metadata.> (2003). "Dismantling the Helsinki Declaration". CMAJ. 169 (10): 997, 999. PMC   236218 . PMID   14609962.
  51. ↑ Emanuel, Ezekiel J.; Miller, Franklin G. (2001). "The Ethics of Placebo-Controlled Trials — A Middle Ground". New England Journal of Medicine. 345 (12): 915–9. doi:10.1056/NEJM200109203451211. PMID   11565527.
  52. ↑ Huston, Patricia; Peterson, Robert (2001). "Withholding Proven Treatment in Clinical Research". New England Journal of Medicine. 345 (12): 912–4. doi:10.1056/NEJM200109203451210. PMID   11565526.
  53. ↑ "WMA - The World Medical Association-Hello world!" (PDF). Archived from the original (PDF) on 2008-11-13. Retrieved 2007-08-21.
  54. ↑ "WMA Press Release: WMA to continue discussion on Declaration of Helsinki. 14 September 2003". Archived from the original on 17 November 2008. Retrieved 24 August 2007.
  55. ↑ "Workgroup report on the revision of paragraph 30 of the Declaration of Helsinki 5 January 2004" (PDF). Archived from the original (PDF) on 7 October 2008. Retrieved 17 August 2008.
  56. 1 2 Blackmer, J.; Haddad, H (2005). "The Declaration of Helsinki: an update on paragraph 30". Canadian Medical Association Journal. 173 (9): 1052–3. doi:10.1503/cmaj.045280. PMC   1266330 . PMID   16247102.
  57. ↑ Lie, R K; Emanuel, E; Grady, C; Wendler, D (2004). "The standard of care debate: the Declaration of Helsinki versus the international consensus opinion". Journal of Medical Ethics. 30 (2): 190–3. doi:10.1136/jme.2003.006031. PMC   1733825 . PMID   15082816.
  58. 1 2 Wolinsky, Howard (2006). "The battle of Helsinki: Two troublesome paragraphs in the Declaration of Helsinki are causing a furore over medical research ethics". EMBO Reports. 7 (7): 670–2. doi:10.1038/sj.embor.7400743. PMC   1500825 . PMID   16819460.
  59. ↑ "WMA Ethics Unit Invitation of Submissions". Archived from the original on 2007-08-17. Retrieved 2007-08-18.
  60. ↑ Schmidt, Harald; Schulz-Baldes, Annette (November 28, 2007). "The 2007 Draft Declaration of Helsinki - Plus ça Change...?". Bioethics Forum. Hastings Center. Archived from the original on July 18, 2011. Retrieved September 3, 2010.
  61. ↑ "Draft revision Nov 2007".[ permanent dead link ]
  62. ↑ "Second draft revision May 2008". Archived from the original on 2011-09-29. Retrieved 2008-06-12.
  63. ↑ Williams J (2008). "The Declaration of Helsinki and public health". Bulletin of the World Health Organization. 86 (8): 650–651. doi:10.2471/BLT.08.050955 (inactive 2 December 2024). PMC   2649471 . PMID   18797627. Archived from the original on August 14, 2008.{{cite journal}}: CS1 maint: DOI inactive as of December 2024 (link)
  64. ↑ "APPI endorses proposed updates to Declaration of Helsinki APPI 22 July 2008" (PDF). Archived from the original (PDF) on 4 July 2011. Retrieved 15 August 2008.
  65. ↑ Eckenwiler, Lisa; Feinholz, Dafna; Ells, Carolyn; Schonfeld, Toby (Spring 2008). "The Declaration of Helsinki through a feminist lens". International Journal of Feminist Approaches to Bioethics . 1 (1): 161–177. doi:10.3138/ijfab.1.1.161. JSTOR   40339217. S2CID   34142927.
  66. ↑ Goodyear MD, Eckenwiler LA, Ells C (2008). "Fresh thinking about the Declaration of Helsinki". BMJ. 337: a2128. doi:10.1136/bmj.a2128. PMID   18930967. S2CID   45673279.
  67. ↑ World Medical Association (2013). "World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects". JAMA. 310 (20): 2191–2194. doi: 10.1001/jama.2013.281053 . hdl: 10818/33790 . PMID   24141714.
  68. ↑ Lurie P, Greco DB (2005). "US exceptionalism comes to research ethics". Lancet. 365 (9465): 1117–9. doi:10.1016/S0140-6736(05)71856-0. PMID   15794954. S2CID   32421380.
  69. ↑ "DHHS FDA 21 CFR part 312 Human Subject Protection: Foreign clinical studies not conducted under an investigational new drug application. Final Rule April 28 2008, effective October 27 2008". Archived from the original on 2008-05-31. Retrieved 2008-05-13.
  70. ↑ "Obasogie O. Goozner on the FDA and the Declaration of Helsinki. Biopolitical Times. Center for Genetics and Society May 15th 2008". Archived from the original on 2009-02-21. Retrieved 2008-08-03.
  71. ↑ Anderson, Matthew (June 1, 2008). "FDA abandons Declaration of Helsinki for international clinical trials". ALAMES: Latin American Social Medicine Association.
  72. ↑ "Global bioethics blog: May 2008".
  73. ↑ "Shah S. FDA Puts Medical Test Subjects in Danger. The Nation May 19, 2008".
  74. ↑ "Trials on trial: The Food and Drug Administration should rethink its rejection of the Declaration of Helsinki". Nature. 453 (7194): 427–8. May 2008. Bibcode:2008Natur.453R.427.. doi: 10.1038/453427b . PMID   18497763.
  75. ↑ "FDA scraps Helsinki Declaration on protecting human subjects. Integrity in Science May 5 2008". Archived from the original on 2008-10-22. Retrieved 2008-08-15.
  76. ↑ Camporesi, Silvia (2009). "The FDA decision to shelve the Helsinki Declaration: Ethical considerations". ecancermedicalscience. 3. doi: 10.3332/eCMS.2008.LTR76 (inactive 1 November 2024).{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
  77. ↑ Kimmelman J, Weijer C, Meslin EM (January 2009). "Helsinki discords: FDA, ethics, and international drug trials". Lancet. 373 (9657): 13–4. doi:10.1016/S0140-6736(08)61936-4. PMID   19121708. S2CID   45220288. Archived from the original on 2023-02-06. Retrieved 2023-02-17.
  78. ↑ Goodyear MD, Lemmens T, Sprumont D, Tangwa G (2009). "Does the FDA have the authority to trump the Declaration of Helsinki?". BMJ. 338: b1559. doi:10.1136/bmj.b1559. PMID   19383751. S2CID   38223712.
  79. ↑ "DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001" (PDF).
  80. ↑ "Research and innovation".
  81. ↑ Rid, Annette; Schmidt, Harald (Spring 2010). "The 2008 Declaration of Helsinki — First among Equals in Research Ethics?". The Journal of Law, Medicine & Ethics. 38 (1): 143–8. doi:10.1111/j.1748-720X.2010.00474.x. PMID   20446992. S2CID   5266004.
  82. ↑ Richards, T (1994-01-22). "The World Medical Association: can hope triumph over experience?". BMJ. 308 (6923): 262–266. doi:10.1136/bmj.308.6923.262. ISSN   0959-8138. PMC   2539333 . PMID   8111265.
  83. 1 2 "WMA - the World Medical Association-Declaration of Helsinki".

Training

Bibliography

Articles

1990-1999

2000-2008

Prior to fifth revision
Following fifth revision
Following sixth revision

WMA

Other codes and regulations

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.